Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort

AIDS Research and Therapy

Volumn 9, Issue , 2012, Pages

  Chua, Arlene C ^a   Llorin, Ryan M ^a   Lai, Kelvin ^a   Cavailler, Philippe ^b   Law, Hwa L ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b Regional Emerging Diseases Intervention Centre   (Singapore)

Author keywords

Antiretrovirals; Kidney; Tenofovir

Indexed keywords

CREATININE; TENOFOVIR; TENOFOVIRDISOPROXILFUMARATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; COCKROFT GAULT EQUATION; CREATININE CLEARANCE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEPHROTOXICITY; PRIORITY JOURNAL; RACE DIFFERENCE; SINGAPORE;

EID: 84862155912     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-9-19     Document Type: Article

References (26)

1. Bucher HC, Wolbers M, Porter K. Guidelines for antiretroviral treatment of HIV from the International AIDS Society-USA Panel. JAMA 2010, 304(17):1897-1898.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2011, Department of Health and Human Services, Editor, Panel on Antiretroviral Guidelines for Adults and Adolescents.
3. World Health Organization HIV/AIDS Department, Antiretroviral Therapy For HIV Infection in Adults and Adolescents, Recommendations for a Public Health Approach 2010, WHO, Editor, World Health Organization.
4. Arribas JR, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008, 47(1):74-78. 10.1097/QAI.0b013e31815acab8, 17971715.
5. Gallant JE, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292(2):191-201. 10.1001/jama.292.2.191, 15249568.
6. Izzedine H, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005, 20(4):743-746. 10.1093/ndt/gfh658, 15741212.
7. Padilla S, et al. Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study. AIDS Patient Care STDS 2005, 19(7):421-424. 10.1089/apc.2005.19.421, 16053398.
8. Barrios A, et al. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004, 18(6):960-963. 10.1097/00002030-200404090-00019, 15060449.
9. Irizarry-Alvarado JM, et al. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. AIDS Read 2009, 19(3):114-121.
10. Izzedine H, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004, 18(7):1074-1076. 10.1097/00002030-200404300-00019, 15096814.
11. Peyriere H, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004, 35(3):269-273. 10.1097/00126334-200403010-00007, 15076241.
12. Quimby D, Brito MO. Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature. AIDS Read 2005, 15(7):357-364.
13. Verhelst D, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002, 40(6):1331-1333. 10.1053/ajkd.2002.36924, 12460055.
14. Williams J, Chadwick DR. Tenofovir-induced renal tubular dysfunction presenting with hypocalcaemia. J Infect 2006, 52(4):e107-e108. 10.1016/j.jinf.2005.07.014, 16125779.
15. Cooper RD, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010, 51(5):496-505. 10.1086/655681, 20673002.
16. Kohler JJ, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 2009, 89(5):513-519. 10.1038/labinvest.2009.14, 2674517, 19274046.
17. Rodriguez-Novoa S, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009, 48(11):e108-e116. 10.1086/598507, 19400747.
18. Goicoechea M, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008, 197(1):102-108. 10.1086/524061, 18171292.
19. Bygrave H, et al. Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho. PLoS One 2011, 6(3):e17609. 10.1371/journal.pone.0017609, 3047584, 21407815.
20. Nishijima T, et al. Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naive patients with HIV infection. PLoS One 2012, 7(1):e29977. 10.1371/journal.pone.0029977, 3252345, 22242194.
21. The HIV Netherlands Australia Thailand Research, Collaboration Tenofovir Renal Toxicity and Glomerular Filtration Rate (GFR) Validation 2011, Available from: http://clinicaltrials.gov/ct2/show/study/NCT01138241, The HIV Netherlands Australia Thailand Research, Collaboration.
22. Levey AS, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130(6):461-470.
23. Levey AS, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145(4):247-254.
24. Zuo L, et al. Application of GFR-Estimating Equations in Chinese Patients With Chronic Kidney Disease. Am J Kidney Dis 2005, 45(3):463-472. 10.1053/j.ajkd.2004.11.012, 15754268.
25. Dauchy FA, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int 2011, 80(3):302-309. 10.1038/ki.2011.124, 21544066.
26. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 2010, 55(1):78-81. 10.1097/QAI.0b013e3181d05579, 20173649.